Linking major depressive disorder pathogenesis with kynurenine pathway - a literature review
DOI:
https://doi.org/10.12775/JEHS.2023.15.01.003Keywords
depression, kynurenine pathway, kynurenine, treatment resistant depression, tryptofan metabolites, kynurenine pathway in depressionAbstract
Introduction: Depressive disorders are a significant problem. They lead to suffering, loss of interest and may contribute to suicide attempts. Despite the large number of available medications, 10-35% of patients fail to achieve remission. Therefore, for these ongoing researches are underway to thoroughly understand the pathophysiology of depression.
Aim of study: The purpose of the study was to review the latest literature on the kynurenine pathway importance in depression, and to discover its links with theories relating to the pathogenesis of depression.
Matherials and methods: A systemic review was conducted using PubMed, ScienceDirect, Google Scholar databases and it was limited to studies published between 2000 and 2023. The search strategy was based on following terms: kynurenine, depression, kynurenine pathway in depression, treatment resistant depression, tryptofan metabolites.
Results: Animal studies confirm the importance of the kynurenine pathway in animal models of depression. Peripherally directed inflammatory stimuli in humans lead to peripheral activation of the kynurenine pathway. The regulation of the kynurenine pathway in the brain is specific to a particular region as well as to a given type of depression.Conclusions: Further studies of the kynurenine pathway targeting different regions of the brain are necessary. Conducting a simultaneous analysis of many central and peripheral tryptofan metabolites will be helpful to accurately determine their mutual impact in both compartments. Understanding changes in kynurenine pathway transmission in a particular type of depression may be helpful in developing new, more effective drugs.
References
Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020 Jan 21; 16:221-234. doi: 10.2147/NDT.S198774. PMID: 32021216; PMCID: PMC6982454.
Organization WH. Depression and Other Common Mental Disorders [Available from: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=D1E4AA0966A230332D86ACB07CFE8150?sequence=1.
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26; 9:90. doi: 10.1186/1741-7015-9-90. PMID: 21791035; PMCID: PMC3163615.
Halaris A, Sohl E, Whitham EA. Treatment-Resistant Depression Revisited: A Glimmer of Hope. J Pers Med. 2021 Feb 23;11(2):155. doi: 10.3390/jpm11020155. PMID: 33672126; PMCID: PMC7927134.
Caraci F., Calabrese F., Molteni R., Bartova L., Dold M., Leggio G.M., Fabbri C., Mendlewicz J., Racagni G., Kasper S., et al. International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacol. Rev. 2018; 70:475–504. doi: 10.1124/pr.117.014977.
Bennabi D, Charpeaud T, Yrondi A, Genty JB, Destouches S, Lancrenon S, Alaïli N, Bellivier F, Bougerol T, Camus V, Dorey JM, Doumy O, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Llorca PM, Courtet P, Aouizerate B, Haffen E. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry. 2019 Aug 28;19(1):262. doi: 10.1186/s12888-019-2237-x. PMID: 31455302; PMCID: PMC6712810.
Sharman Moser S, Chodick G, Gelerstein S, Barit Ben David N, Shalev V, Stein-Reisner O. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. BMC Psychiatry. 2022 Aug 11;22(1):541. doi: 10.1186/s12888-022-04184-8. PMID: 35948895; PMCID: PMC9367052.
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. (2020) 396:1204–22. 10.1016/S0140-6736(20)30925-9.
Kautzky A, Baldinger-Melich P, Kranz GS, Vanicek T, Souery D, Montgomery S, et al. A New Prediction Model for Evaluating Treatment-Resistant Depression. J Clin Psychiatry. 2017;78(2):215–222. doi: 10.4088/JCP.15m10381.
Asami, Y., Goren, A., & Okumura, Y. (2015). Work Productivity Loss with Depression, Diagnosed and Undiagnosed, Among Workers in an Internet-Based Survey Conducted in Japan. Journal of Occupational and Environmental Medicine, 57(1), 105–110. doi:10.1097/jom.0000000000000310.
Bouwmans, C. A. M., Vemer, P., van Straten, A., Tan, S. S., & Hakkaart-van Roijen, L. (2014). Health-Related Quality of Life and Productivity Losses in Patients with Depression and Anxiety Disorders. Journal of Occupational and Environmental Medicine, 56(4), 420–424. doi:10.1097/jom.0000000000000112.
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070.
Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(8):17.
Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/.
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM Jr, Schatzberg AF. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry. 2017 Apr;22(4):527-536. doi: 10.1038/mp.2016.120. Epub 2016 Aug 16. PMID: 27528460; PMCID: PMC5313380.
Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(8):17.
Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord. 2011;13(3): PCC.10m01082. doi: 10.4088/PCC.10m01082. PMID: 21977377; PMCID: PMC3184569.
Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: Definitions and characteristics. Depress Anxiety.
Souery D, Lipp O, Massat I, Mendlewicz J. The characterization and definition of treatment-resistant mood disorders. Treatment-resistant mood disorders Cambridge, UK. 2001:3–29.
Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–971. doi: 10.4088/JCP.v63n1102.
Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014 Aug;121(8):907-24. doi: 10.1007/s00702-013-1130-x. Epub 2013 Dec 8. PMID: 24318540; PMCID: PMC4048804.
Jasionowska J, Filip M, Talarowska M, Gałecki P. Znaczenie szlaku kynureninowego w zaburzeniach depresyjnych [The importance of the kynurenine pathway in depressive disorders]. Pol Merkur Lekarski. 2018 Aug 29;45(266):89-93. Polish. PMID: 30240376.
Pu J, Liu Y, Zhang H, Tian L, Gui S, Yu Y, Chen X, Chen Y, Yang L, Ran Y, Zhong X, Xu S, Song X, Liu L, Zheng P, Wang H, Xie P. An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder. Mol Psychiatry. 2021 Aug;26(8):4265-4276. doi: 10.1038/s41380-020-0645-4. Epub 2020 Jan 20. PMID: 31959849; PMCID: PMC8550972.
Höglund E, Øverli Ø, Winberg S. Tryptophan Metabolic Pathways and Brain Serotonergic Activity: A Comparative Review. Front Endocrinol (Lausanne). 2019 Apr 8;10:158. doi: 10.3389/fendo.2019.00158. PMID: 31024440; PMCID: PMC6463810.
Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938. doi: 10.1177/1178646917691938. PMID: 28469468; PMCID: PMC5398323.
Yuasa HJ, Ball HJ. Efficient tryptophan-catabolizing activity is consistently conserved through evolution of TDO enzymes, but not IDO enzymes. J Exp Zool B Mol Dev Evol. 2015 Mar;324(2):128-40. doi: 10.1002/jez.b.22608. Epub 2015 Feb 20. PMID: 25702628.
Percudani R, Peracchi A. A genomic overview of pyridoxal-phosphate-dependent enzymes. EMBO Rep. 2003 Sep;4(9):850-4. doi: 10.1038/sj.embor.embor914. PMID: 12949584; PMCID: PMC1326353.
Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology. 2017 Jan;112(Pt B):248-263. doi: 10.1016/j.neuropharm.2015.11.015. Epub 2015 Nov 23. PMID: 26617070..
Martín-Hernández D, Tendilla-Beltrán H, Madrigal JLM, García-Bueno B, Leza JC, Caso JR. Chronic Mild Stress Alters Kynurenine Pathways Changing the Glutamate Neurotransmission in Frontal Cortex of Rats. Mol Neurobiol. 2019 Jan;56(1):490-501. doi: 10.1007/s12035-018-1096-7. Epub 2018 May 3. PMID: 29725904.
Lawson MA, Parrott JM, McCusker RH, Dantzer R, Kelley KW, O'Connor JC. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation. 2013 Jul 18;10:87. doi: 10.1186/1742-2094-10-87. PMID: 23866724; PMCID: PMC3733827.
Duda W, Curzytek K, Kubera M, Connor TJ, Fagan EM, Basta-Kaim A, Trojan E, Papp M, Gruca P, Budziszewska B, Leśkiewicz M, Maes M, Lasoń W. Interaction of the immune-inflammatory and the kynurenine pathways in rats resistant to antidepressant treatment in model of depression. Int Immunopharmacol. 2019 Aug;73:527-538. doi: 10.1016/j.intimp.2019.05.039. Epub 2019 Jun 5. PMID: 31176083.
Millischer V, Heinzl M, Faka A, Resl M, Trepci A, Klammer C, Egger M, Dieplinger B, Clodi M, Schwieler L. Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial. J Neuroinflammation. 2021 Jul 17;18(1):158. doi: 10.1186/s12974-021-02196-x. PMID: 34273987; PMCID: PMC8286561.
Kruse JL, Cho JH, Olmstead R, Hwang L, Faull K, Eisenberger NI, Irwin MR. Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study. Psychoneuroendocrinology. 2019 Nov; 109:104371. doi: 10.1016/j.psyneuen.2019.104371. Epub 2019 Jul 3. PMID: 31325802; PMCID: PMC6842695.
Wu Y, Mai N, Zhong X, Wen Y, Zhou Y, Li H, Shang D, Hu L, Chen X, Chen B, Zhang M, Ning Y. Kynurenine pathway changes in late-life depression with memory deficit. Psychiatry Res. 2018 Nov;269:45-49. doi: 10.1016/j.psychres.2018.08.041. Epub 2018 Aug 13. PMID: 30145300.
Colle R, Masson P, Verstuyft C, Fève B, Werner E, Boursier-Neyret C, Walther B, David DJ, Boniface B, Falissard B, Chanson P, Corruble E, Becquemont L. Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case-control study. Psychiatry Clin Neurosci. 2020 Feb;74(2):112-117. doi: 10.1111/pcn.12944. Epub 2019 Nov 2. PMID: 31599111.
Marx W, McGuinness AJ, Rocks T, Ruusunen A, Cleminson J, Walker AJ, Gomes-da-Costa S, Lane M, Sanches M, Diaz AP, Tseng PT, Lin PY, Berk M, Clarke G, O'Neil A, Jacka F, Stubbs B, Carvalho AF, Quevedo J, Soares JC, Fernandes BS. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021 Aug;26(8):4158-4178. doi: 10.1038/s41380-020-00951-9. Epub 2020 Nov 23. PMID: 33230205.
Pu J, Liu Y, Zhang H, Tian L, Gui S, Yu Y, Chen X, Chen Y, Yang L, Ran Y, Zhong X, Xu S, Song X, Liu L, Zheng P, Wang H, Xie P. An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder. Mol Psychiatry. 2021 Aug;26(8):4265-4276. doi: 10.1038/s41380-020-0645-4. Epub 2020 Jan 20. PMID: 31959849; PMCID: PMC8550972.
Almulla AF, Thipakorn Y, Vasupanrajit A, Abo Algon AA, Tunvirachaisakul C, Hashim Aljanabi AA, Oxenkrug G, Al-Hakeim HK, Maes M. The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis. Brain Behav Immun Health. 2022 Oct 21; 26:100537. doi: 10.1016/j.bbih.2022.100537. PMID: 36339964; PMCID: PMC9630622.
Brown SJ, Huang XF, Newell KA. The kynurenine pathway in major depression: What we know and where to next. Neurosci Biobehav Rev. 2021 Aug;127:917-927. doi: 10.1016/j.neubiorev.2021.05.018. Epub 2021 May 23. PMID: 34029552.
Paul ER, Schwieler L, Erhardt S, Boda S, Trepci A, Kämpe R, Asratian A, Holm L, Yngve A, Dantzer R, Heilig M, Hamilton JP, Samuelsson M. Peripheral and central kynurenine pathway abnormalities in major depression. Brain Behav Immun. 2022 Mar; 101:136-145. doi: 10.1016/j.bbi.2022.01.002. Epub 2022 Jan 6. PMID: 34999196; PMCID: PMC9045681.
Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Träskman-Bendz L, Guillemin GJ, Brundin L. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013 Apr;38(5):743-52. doi: 10.1038/npp.2012.248. Epub 2012 Dec 3. PMID: 23299933; PMCID: PMC3671988.
Clark SM, Pocivavsek A, Nicholson JD, Notarangelo FM, Langenberg P, McMahon RP, Kleinman JE, Hyde TM, Stiller J, Postolache TT, Schwarcz R, Tonelli LH. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci. 2016 Oct;41(6):386-394. doi: 10.1503/jpn.150226. PMID: 27070351; PMCID: PMC5082509.
Brown SJ, Brown AM, Purves-Tyson TD, Huang XF, Shannon Weickert C, Newell KA. Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. J Psychiatr Res. 2022 Mar;147:203-211. doi: 10.1016/j.jpsychires.2021.12.039. Epub 2021 Dec 21. PMID: 35063739.
Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011 Aug 10;8:94. doi: 10.1186/1742-2094-8-94. Erratum in: J Neuroinflammation. 2013;10:34. PMID: 21831269; PMCID: PMC3177898
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Dominik Szawica, Aleksandra Kuźniar, Kamila Fularska, Michał Oleszko, Edward Wąsiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 446
Number of citations: 0